Drugs / Calculus bovis sativus
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07080632 | Oct 2025 → Mar 2026 overdue | intracerebral hemorrhage | Tongji Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07085962 | Aug 2025 → Mar 2026 overdue | metabolic dysfunction-associated steatotic liver disease | Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
| — | NCT06584045 | Sep 2024 → Jul 2029 expected | anti-NMDA receptor encephalitis, autoimmune encephalitis, viral encephalitis | Tongji Hospital | Recruiting | No outcome recorded |
| — | NCT06474507 | Aug 2024 → Jul 2029 expected | ischemic stroke | Tongji Hospital | Recruiting | No outcome recorded |
| — | NCT06474520 | Aug 2024 → Jul 2029 expected | acute disseminated encephalomyelitis, multiple sclerosis, myelin oligodendrocyte glycoprotein antibody-associated disease, neuromyelitis optica | Tongji Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Calculus bovis sativus | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06474507 ↗ |
| Known as | CBS | “Calculus Bovis Sativus (CBS) is the most authentic formulation of bezoar ingredients compared to other bezoar products.” NCT07080632 ↗3“Drug: Calculus bovis sativus (CBS)” NCT06584045 ↗ “Calculus bovis sativus (CBS)” NCT06474520 ↗ “Calculus bovis sativus (CBS)” NCT06474507 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “According to historical Chinese medical documents, bezoar possesses properties that can help prevent seizures, treat strokes, enhance cognitive function and mental well-being,...” NCT06474507 ↗ |
| Route | Oral | “Subjects will orally receive 100mg CBS per day from day 1 to day 84.” NCT06474507 ↗ |